FiercePharma, by Arlene Weintraub, Jan 25, 2019 AbbVie investors have been bracing for the mother of all patent cliffs—the loss of exclusivity on the company’s $18-billion-per-year Humira—and now its impact is starting to come into view. The mass exodus from the branded product to biosimilars confirms what AbbVie’s executives have already admitted, which is that their […]
Reuters, Andrew Chung, Jun 12, 2017 The U.S. Supreme Court on Monday cut the time it will take for copycat versions of biologic drugs to get to the market in a pivotal ruling about an expensive class of medicines that can yield billions of dollars in sales for drug companies. The justices, in a 9-0 […]
10. Aug. 2016, FiercePharma, Tracy Staton Copay discount programsbecome popular among biosimilar manufacturers to boost the adoption of their products. These copay assistence programs can come in form of upfront out-of-pocket financial support (e.g. Sun Pharmaceuticals for their Gleevec-alike imatinib mesylate) or the reduction of upfront cost to the patients (e.g. the cost of the […]